Home

Mark J Rosenblum

CIK 1329154 · Chief Financial Officer · last filed 2026-09-02

Mark J Rosenblum is a Chief Financial Officer who has filed 33 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for DCOY, was dated Sep 2, 2026. Across all open-market trades the lifetime net is +$110.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $30.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$30.3K

Companies

3

Total Filings

33

Lifetime Open-Market Net

$110.0K

Filer Profile

Reported Address
3990 SPRING VALLEY ROAD, APT. 1218
DALLAS, TX 75244
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DCOY Chief Financial Officer 11,363 $2.67 $30.3K $0 1 2026-09-02
Salarius Pharmaceuticals, Inc. (SLRX) Delisted Exec VP Finance, CFO 20,177 $0.84 $16.9K $62.0K 20 2025-11-20
Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Chief Financial Officer 113,774 — — $48.0K 4 2014-02-04

Recent Filings

33 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 DCOY Grant (A) +9,682 $0 EDGAR
2025-11-20 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Buy (P) +20,000 $16.0K EDGAR
2024-02-22 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) — $0 EDGAR
2023-02-15 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +6,432 $0 EDGAR
2023-01-05 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +8,000 $0 EDGAR
2022-12-12 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +1,488 $2.6K EDGAR
2022-11-08 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +7,314 $12.7K EDGAR
2022-11-07 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +7,314 $12.7K EDGAR
2022-05-31 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Buy (P) +28,000 $5.0K EDGAR
2022-05-05 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +10,000 $1.9K EDGAR
Showing 1–10 of 33
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.